Feature

Opioid prescribing mapped: Alabama highest, New York lowest


 

Medicare beneficiaries in Alabama were more likely to get a prescription for an opioid than in any other state in 2019, based on newly released data.

Opioid prescribing rates for Medicare part D in 2019

That year, opioids represented 6.48% of all drug claims for part D enrollees in the state, just ahead of Utah at 6.41%. Idaho, at 6.07%, was the only other state with an opioid prescribing rate over 6%, while Oklahoma came in at an even 6.0%, according to the latest update of the Centers for Medicare & Medicaid Services’ dataset.

The lowest rate in 2019 belonged to New York, where 2.51% of drug claims, including original prescriptions and refills, involved an opioid. Rhode Island was next at 2.87%, followed by New Jersey (3.23%), Massachusetts (3.26%), and North Dakota (3.39%),

Altogether, Medicare part D processed 1.5 billion drug claims in 2019, of which 66.1 million, or 4.41%, involved opioids. Both of the opioid numbers were down from 2018, when opioids represented 4.68% (70.2 million) of the 1.5 billion total claims, and from 2014, when opioids were involved in 5.73% (81,026,831) of the 1.41 billion drug claims, the CMS data show. That works out to 5.77% fewer opioids in 2019, compared with 2014, despite the increase in total volume.

Among the states, Delaware had the largest 5-year decrease, 2.38 percentage points, as its opioid prescribing rate dropped from 6.61% to 4.23% from 2014 to 2019, with Hawaii showing the smallest decline as it slipped 0.41 percentage points from 3.9% to 3.49%, according to the CMS.

In 2019, part D beneficiaries in Vermont were the most likely to receive a long-acting opioid, which accounted for 20.14% of all opioid prescriptions in the state, while Kentucky had the lowest share of prescriptions written for long-acting forms at 6.41%. The national average was 11.02%, dropping from 11.79% in 2018 and 12.75% in 2014, the CMS reported.

Recommended Reading

High variability found in studies assessing hemophilia-related pain
MDedge Hematology and Oncology
Pediatric cancer survivors at risk for opioid misuse
MDedge Hematology and Oncology
Photobiomodulation: Evaluation in a wide range of medical specialties underway
MDedge Hematology and Oncology
Infusion centers may best EDs for treating sickle cell crises
MDedge Hematology and Oncology
‘Long haul’ COVID recovery worse than cancer rehab for some: CDC
MDedge Hematology and Oncology
Sharp decrease in opioid access for dying U.S. cancer patients
MDedge Hematology and Oncology
Opioid prescribing laws having an impact
MDedge Hematology and Oncology
EDs saw more benzodiazepine overdoses, but fewer patients overall, in 2020
MDedge Hematology and Oncology
Guideline gives weak support to trying oral medical cannabis for chronic pain
MDedge Hematology and Oncology
Opioid prescriptions following Mohs surgery dropped over the last decade
MDedge Hematology and Oncology